Enliven Therapeutics
ELVN
ELVN
31 hedge funds and large institutions have $8.78M invested in Enliven Therapeutics in 2022 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
less ownership
Funds ownership: →
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
66% less call options, than puts
Call options by funds: $939K | Put options by funds: $2.73M
Holders
31
Holding in Top 10
–
Calls
$939K
Puts
$2.73M
Top Buyers
| 1 | +$479K | |
| 2 | +$388K | |
| 3 | +$238K | |
| 4 |
Parallax Volatility Advisers
San Francisco,
California
|
+$226K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$217K |
Top Sellers
| 1 | -$1.23M | |
| 2 | -$1.14M | |
| 3 | -$1.06M | |
| 4 |
Two Sigma Advisers
New York
|
-$223K |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$194K |